Phase I & II clinical trial expertise

Our substantial experience of developing and conducting adaptive protocols for Phase I and II trials enables us to maximise the return on our sponsors’ studies whilst guaranteeing the safety of our participants.


Benefits of using our Phase I & II clinical trials

Adding value by gathering more and highly relevant data. We only collect and analyse essential data to meet the trial objectives within a limited budget.

We limit assessments and participant exposure to what is relevant and essential. Tailoring our adaptive limits and control mechanisms for each protocol to manage potential risks.

Umbrella protocols to maximise efficiency. We integrate ethnic comparison elements, intensive cardiac assessments, and other biomarkers into a combined umbrella protocol - avoiding potential risks in further drug development.

We maximise return on our sponsors' trials

Using adaptive design to support rational “no-go” or “where to go next” decisions, an entire early phase programme from First-In-Human to Proof of Concept can be performed in one trial protocol, in one trial centre.

Get in touch today

Why choose Richmond Pharmacology for your Early Phase Studies


Systematic and logical protocols

We adapt the trial design whilst maintaining the validity of the data and integrity of the trial.

Read more +

Competent and fast decisions

We guarantee rapid progression of your trial.

Read more +

Rapid approval

We have an excellent track record for starting studies on time and effectively managing ethics and regulatory submissions.

Read more +

Time efficient

Fast and efficient adaptive protocol development using a transparent and systematic approach.

Read more +

Our adaptive protocols enable immediate implementation of adaptive changes leading to early decision making and efficient use of essential data outputs.

Latest news

Celebrating Clinical Trials Day 2023

May 19, 2023
This year, we will be celebrating Clinical Trials Day alongside our workforce, sponsors and industry colleagues.
Read more

Futureproofing early phase clinical research for the next generation of investigators.

March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Read more


HFA Annual Meeting 2023

Saturday 20th May 2023 - Tuesday 23rd May 2023
Join Dr Taubel at the HFA Annual Meeting in Prague
View event